Chrysotobibenzyl

Chrysotobibenzyl, a bibenzyl found in the stem of Dendrobium pulchellum, may facilitate anoikis and inhibit the growth of lung cancer cells in anchorage-independent condition. Chrysotobibenzyl is therefore used in cancer metastasis research models to investigate anoikis-associated cell death mechanisms and anchorage-independent growth regulation in lung cancer cell systems. Chrysotobibenzyl is also applied in extracellular matrix detachment studies to evaluate survival signaling changes under non-adherent cellular conditions.

Method: Human lung cancer cells (H460, H292, A549, H23) and non-cancerous human cells (HCT116, primary DP1, DP2) were treated with chrysotobibenzyl (0–50 µM) for 48 h to assess cytotoxicity, proliferation, migration, invasion, filopodia formation, EMT markers, and signaling protein levels. shRNA-Cav-1-transfected H460 and H292 cells were also generated to assess effects on migration and integrin expression.
Result: Chrysotobibenzyl was non-cytotoxic in all tested cancer and non-cancerous cell lines. At 50 µM, it significantly altered cell proliferation in H292 cells at 48 h. At 1–50 µM, it significantly inhibited H460 and H292 cell migration, invasion, filopodia formation, and EMT in a dose-dependent manner at 48 h, associated with reduced integrins β1, β3, αν, p-FAK, p-AKT, Cdc42, and Cav-1 protein levels. shCav-1-transfected cells showed decreased migration and reduced integrins β1, β3, and αν compared with control cells. Chrysotobibenzyl reduced EMT markers Vimentin, Snail, and Slug, and increased sensitivity of lung cancer cells to cisplatin-induced apoptosis.